Natalizumab antibody | AbD21384_hIgG1
A microtiter plate was coated over night with various antigens at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP conjugated Human anti natalizumab (clone AbD21384_hIgG1) at a concentration of 2 μg/ml, in HISPEC assay diluent (BUF049A) and QuantaBlu fluorogenic peroxidase substrate. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit.
A microtiter plate was coated over night with natalizumab, human IgG1/kappa or human IgG1/lambda at a concentration of 5 μg/ml. After washing and blocking with PBST+5% BSA, detection was performed using HRP conjugated Human anti natalizumab (clone AbD21384_hIgG1) titrated to the given concentrations in PBST, followed by QuantaBlu fluorogenic peroxidase substrate. HRP-conjugation of the antibody used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit. Data is presented as the mean of three measurements.
A microtitre plate was coated over night with natalizumab at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, 10% human serum was added spiked with increasing concentrations of Human anti natalizumab, clone AbD21375_hIgG1 (HCA249) or clone AbD21384_hIgG1 (HCA250). Detection was performed using HRP-conjugated natalizumab. HRP-conjugation of natalizumab used in this assay was performed using a LYNX Rapid HRP Antibody Conjugation Kit. Data is presented as the mean of three measurements.
A microtiter plate was coated over night with alpha-4/beta-1 integrin at a concentration of 1 μg/ml. After washing and blocking with PBST+5% BSA, a pre-incubated mixture of natalizumab (0.3 μg/ml) plus increasing concentrations of Human anti natalizumab in its monovalent Fab format was added (clone AbD21384). Free natalizumab, still capable of binding to the alpha-4/beta-1 integrin coated plate, was detected using Mouse anti Human IgG (Fc) CH2 domain:HRP (MCA647P) and QuantaBlu fluorogenic peroxidase substrate. Data is presented as the mean of three measurements.
Human anti Natalizumab
- Product Type
- Monoclonal Antibody
- Clone
- AbD21384_hIgG1
- Isotype
- IgG1
- Specificity
- Natalizumab
Antibody Quality and Performance Guarantee
| Human Anti-Natalizumab Antibody, clone AbD21384_hlgG1 is a paratope specific, anti-idiotypic antibody that specifically recognizes free natalizumab but not free human alpha-4/beta-1 integrin or the drug/integrin complex. It inhibits the binding of natalizumab to its target and can be used to measure levels of free natalizumab and biosimilar products in bioanalytical and patient monitoring assays. Clone AbD21384_hIgG1 is a fully human recombinant monoclonal antibody with IgG1 isotype and is suitable as a surrogate positive control or calibrator of medium affinity in an anti-drug antibody (ADA) assay. Natalizumab (Tysabri) is a humanized IgG4/kappa monoclonal antibody approved as a monotherapy for the treatment of relapsing forms of multiple sclerosis and for the treatment of Crohn’s disease. It is directed against alpha-4 integrin (CD49d), and binds to alpha-4/beta-1 integrin on the surface of circulating leucocytes, except neutrophils. It is believed to act by blocking the interaction of alpha-4/beta-1 integrin with vascular cell adhesion molecule-1 (VCAM-1), preventing the adherence and transport of inflammatory immune cells across the intestinal lining and blood-brain barrier. View a summary of all anti-natalizumab antibodies. |
|
- Product Form
- Human IgG1 antibody (lambda light chain) selected from the HuCAL phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
- Preparation
- Purified IgG prepared by affinity chromatography on Protein A
- Source
- HKB-11
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
- Immunogen
- Natalizumab
- Affinity
- The intrinsic affinity of the monovalent form of this antibody is KD = 12.2 nM as measured by real time, label free molecular interaction analysis on immobilized natalizumab.
- Approx. Protein Concentrations
- Antibody concentration 0.5 mg/ml
- Regulatory
- For research purposes only
- Guarantee
- 12 months from date of despatch
- Acknowledgements
- This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.
Tysabri is a registered trademark Biogen Idec and Elan. - Licensed Use
- For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA |  |
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.
- Technical Advice
- Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the HuCAL Antibodies Technical Manual.
- ELISA
- This product may be used in a direct ELISA or as a detection reagent in a bridging ELISA together with HCA248 as the capture reagent.
Protocol: PK bridging ELISA to measure free drug.
This antibody is fully human and can be used as a reference standard in an ADA assay.
Protocol: ADA bridging ELISA.
- Synonyms
- TYSABRI®
HCA250
0614
162271
168785
If you cannot find the batch/lot you are looking for please contact our technical support team for assistance.
View more products with NATALIZUMAB specificity
Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"
Always be the first to know.
When we launch new products and resources to help you achieve more in the lab.
Yes, sign me up